Moderna will pay up to $2.25B to settle a patent lawsuit over lipid nanoparticle technology used in its COVID-19 vaccine.

Transformative Biotech LLC, a Boulder-based company working to develop faster molecular tests for diseases such as COVID-19 and cancer, has appointed Mark Kelleher as executive vice president of ...

BOSTON, MA / ACCESS Newswire / March 2, 2026 / Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company ...

The settlement, which requires Moderna to pay the plaintiffs $950 million upfront plus up to $1.3 billion in contingent commitments, is an outcome “better than feared,” according to analysts.

NEW YORK -- The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the ...

Mast interviewed more than two dozen former and current Moderna employees, along with analysts, rival executives, investors, and experts in mRNA and vaccines to understand how the company arrived at ...

Promoted by Dr Krishna Ella, the vaccine manufacturer serves both domestic and export markets and remains entirely ...

Updated 2024-2025 COVID-19 vaccines significantly reduced the risk for hospitalization and severe outcomes despite the emergence of new viral lineages.

Moderna has reached a major legal settlement worth up to $2.25 billion with Genevant Sciences and Arbutus Biopharma, ending a long-running patent dispute over the lipid nanoparticle (LNP) technology ...